Open Access<p>Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review</p>
Author(s) -
Na Li,
Huanrui Zheng,
Bin Zheng,
Chaoxin Chen,
Hongfu Cai,
Maobai Liu
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s248020
Subject(s) - pembrolizumab , atezolizumab , nivolumab , medicine , lung cancer , oncology , checklist , cost effectiveness , population , meta analysis , cancer , intensive care medicine , immunotherapy , environmental health , psychology , risk analysis (engineering) , cognitive psychology
This review aimed to assess the quality of available evidence on the economic evaluations of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and provide evidence to improve the efficiency of healthcare resources.